Company attributes
Venture Capital Firm attributes
Other attributes
Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early-stage opportunities access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson.
In June 2013, Johnson & Johnson Innovation announced the opening of the Johnson & Johnson California Innovation Center, one of four regional hubs being established. A part of Johnson & Johnson Innovation, the goal of the California Innovation Center is to advance healthcare by catalyzing collaborations in science and technology between regional innovators and the Johnson & Johnson Family of Companies.
In March 2015, Johnson & Johnson Innovation LLC announced the opening of JLABS in South San Francisco. The Johnson & Johnson Innovation, JLABS site can accommodate up to 50 startups from across the healthcare spectrum including biotech, pharmaceutical, medical device, consumer and digital health.
JLABS provides tools and resources to help life science startups. Residents have access to infrastructure as well as year-round commercialization curriculum and networking events, onsite team for operations and business services. JLABS links regional entrepreneurs with the full breadth of Johnson & Johnson Innovation, including opportunities to discuss funding, access third-party services, attend educational events and meet with R&D experts from medical device technology, consumer healthcare product and Janssen pharmaceutical teams.
In June 2018, Johnson & Johnson Innovation's outpost of its startup incubator, JLabs, opened in Manhattan . In addition to NYC, there are JLabs in San Diego, San Francisco, Toronto, Houston, Boston and Belgium as well as another planned in Shanghai. The incubators provide J&J, one of the largest pharmaceutical companies in the world, with a view of what's happening at the startup level. Though J&J doesn't take an immediate stake in the companies, it does end up investing in some in the long-run.
